

## Disclosures

### Personal Commercial (12)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
ACI Clinical	Other - <i>Adjudication Committee</i>	Significant (>= \$5,000)	<i>Acute Coronary Syndromes</i>
AHA	Other - <i>Deputy Editor Circulation Heart Failure</i>	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Amgen Inc.	Other - <i>Steering Committee</i>	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
AstraZeneca Pharmaceuticals	Other - <i>Steering Committee</i>	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Boehringer-Ingelheim	Data Safety Monitoring Board	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
HFSA	Officer, Director, Trustee, or other Fiduciary Role	None (\$0)	<i>Heart Failure and Cardiomyopathies</i>
National Institutes of Health	Other - <i>TRANSFORM-HF trial site PI</i>	None (\$0)	<i>Heart Failure and Cardiomyopathies</i>
National Institutes of Health	Other - <i>OSMB Member</i>	Modest (< \$5,000)	<i>Invasive CV Angio and Interventions</i>
National Institutes of Health	Research/Research Grants	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
National Institutes of Health	Data Safety Monitoring Board	Modest (< \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
UpToDate	Other - <i>Topic Author</i>	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Windtree	Data Safety Monitoring Board	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (1)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
HFSA † HFSA	Officer, Director, Trustee, or other Fiduciary Role	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (1)

Funding Source	Institutional Compensation Level
University of Utah	Significant (>= \$5,000)

### Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

## Agreement

**Certified Education Attestation** | Signed on 7/29/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 7/29/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

**Embargo** | Signed on 7/29/2024

## On-Going Obligation Agreement | Signed on 7/29/2024

---

### ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.